OncLive TV

Andre H. Goy, MD, discusses the clinical data reported with axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma and real-world findings with brexucabtagene autoleucel in mantle cell lymphoma.

David Sallman, MD, discusses responses achieved a first-in-human dose escalation/dose expansion phase 1/1b clinical trial of an UltraCAR-T agent, PRGN-3006, in patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome with hypomethylating agent failure.

John F. Seymour, discusses the findings from a post-hoc analysis of the phase 3 ELEVATE-RR trial examining the adverse effects experienced with the BTK inhibitors acalabrutinib and ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia.

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

James K. McCloskey, MD, discusses the utility of decitabine plus cedazuridine in lower-risk myelodysplastic syndromes, based on data from the long-term follow-up of the phase 3 ASCERTAIN trial.

Susan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.

Kristen K. Ciombor, MD, MSCI, discusses data evaluating the utility of rechallenging with EGFR inhibitors in RAS/RAF wild-type colorectal cancer.

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Andrew Matthews, MD, discusses the efficacy of CPX-351 vs venetoclax plus azacitidine in acute myeloid leukemia.

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Lori A. Leslie, MD, discusses results from the primary analysis of the phase 3 ZUMA‑7 trial, which evaluated axicabtagene ciloleucel vs standard‑of‑care therapy in patients with relapsed or refractory large B-cell lymphoma.

Michael Choi, MD, discusses the long-term efficacy of ibrutinib given as a frontline treatment in chronic lymphocytic leukemia.

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Guenther Koehne, MD, PhD, discusses the real-life study of CAR T-cell agents axicabtagene ciloleucel vs tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma.

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

Daniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Jan A. Burger, MD, PhD, discusses choosing frontline therapy in chronic lymphocytic leukemia.

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, chief, discusses the importance of evaluating enobosarm in metastatic estrogen receptor–positive, HER2-negative breast cancer.

Marshall Posner, MD, shares his clinical experience with the use of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Lori J. Wirth, MD, discusses the utility of tipifarnib in patients with head and neck cancer whose tumors harbor HRAS mutations.

Alessandra Larocca, MD, PhD, discusses the various factors to consider when selecting treatment for difficult-to-treat patients with relapsed/refractory multiple myeloma.

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.

Ashish Manne, MBBS, discusses the need to develop novel therapies for patients with hepatocellular carcinoma without preserved liver function.

Marina Kremyanskaya, MD, PhD, discusses the next steps of the phase 1/2 MANIFEST trial in myelofibrosis.

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.